Research Article

Genome-Wide Expression Profiling of Anoxia/Reoxygenation in Rat Cardiomyocytes Uncovers the Role of MitoK\textsubscript{ATP} in Energy Homeostasis

Song Cao,\textsuperscript{1,2} Yun Liu,\textsuperscript{2,3} Wenting Sun,\textsuperscript{1,2} Li Zhao,\textsuperscript{1,2} Lin Zhang,\textsuperscript{1,2} Xinkui Liu,\textsuperscript{1} and Tian Yu\textsuperscript{1,2}

\textsuperscript{1}Department of Anesthesiology, Zunyi Medical College, Zunyi 563000, China
\textsuperscript{2}Guizhou Key Laboratory of Anesthesiology and Organ Protection, Zunyi Medical College, Zunyi 563000, China
\textsuperscript{3}Research Center for Medicine & Biology, Zunyi Medical College, Zunyi 563000, China

Correspondence should be addressed to Tian Yu; zyyutian@126.com

Received 16 September 2014; Accepted 8 December 2014

Academic Editor: Yanfang Chen

Copyright © 2015 Song Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mitochondrial ATP-sensitive potassium channel (mitoK\textsubscript{ATP}) is a common end effector of many protective stimuli in myocardial ischemia-reperfusion injury (MIRI). However, the specific molecular mechanism underlying its myocardial protective effect is not well elucidated. We characterized an anoxia/reoxygenation (A/R) model using freshly isolated adult rat cardiomyocytes. MitoK\textsubscript{ATP} status was interfered with its specific opener diazoxide (DZ) or blocker 5-hydroxydecanote (5-HD). Digital gene expression (DGE) and bioinformatic analysis were deployed. Three energy metabolism related genes (MT-ND6, Idh2, and Acadl) were upregulated when mitoK\textsubscript{ATP} opened. In addition, as many as 20 differentially expressed genes (DEGs) were significantly enriched in five energy homeostasis correlated pathways (PPAR, TCA cycle, fatty acid metabolism, and peroxisome). These findings indicated that mitoK\textsubscript{ATP} opening in MIRI resulted in energy mobilization, which was confirmed by measuring ATP content in cardiomyocytes. These causal outcomes could be a molecular mechanism of myocardial protection of mitoK\textsubscript{ATP} and suggested that the mitoK\textsubscript{ATP} opening plays a physiologic role in triggering cardiomyocytes’ energy homeostasis during MIRI. Strategies of modulating energy expenditure during myocardial ischemia-reperfusion may be promising approaches to reduce MIRI.

1. Introduction

Myocardial infarction has been a leading cause of death worldwide. The prognosis of acute myocardial infarction has been dramatically improved due to the advances of both catheterization techniques and reperfusion therapy by coronary mechanical and pharmacological intervention methods. However, strategies to limit myocardial ischemia-reperfusion injury (MIRI), thus reducing infarct size, have not been well applied in clinical settings.

Although myocardial ischemia-reperfusion (IR) induces lethal injury in the heart, after some artificial interventions, the cardiomyocytes and the heart tissue therein have powerful endogenous mechanisms to protect themselves from oxidative stress, energy deficiency, protein aggregation, and organelle malfunction, thereby minimizing MIRI [1]. For example, Murry et al. in 1990 [2, 3] first proposed that ischemic preconditioning (IPC) may protect the heart by reducing myocardial energy demand during myocardial ischemia and decreasing cell death by preserving ATP content and/or reducing catabolite accumulation. Following the discovery of the mitoK\textsubscript{ATP} channel locating at the inner mitochondrial membrane in 1991 [4], Garlid et al. and Liu et al. [5, 6] demonstrated it as a trigger of IPC. Pharmacological intervention mimicking the IPC has currently been considered as a promising modality for the treatment of MIRI. Similar myocardial protection can be produced by drugs such as diazoxide (DZ) that open mitoK\textsubscript{ATP} [5, 7]. Conversely, mitoK\textsubscript{ATP} blockers (5-hydroxydecanote (5-HD) or glibenclamide) cancelled the effect of preconditioning and pharmacological cardioprotection [5, 6, 8]. It is also demonstrated that the pharmacological inhibition of the mitoK\textsubscript{ATP} in early reperfusion abolished the infarct-limiting effects of IPoM [9–11].
We have reported that mitoK$_{\text{ATP}}$ opening was cardio-protective in MIRI [12–14], but our understanding of its specific mechanism remained quite preliminary. To date, the main proposed mechanisms of cardioprotection by mitoK$_{\text{ATP}}$ were various: swelling of mitochondria increased fatty acid oxidation (FAO), mitochondrial respiration, and ATP production [15]; inhibition of ATP hydrolysis during ischemia [16, 17] preserved ATP and decreased Ca$^{2+}$ uptake in the cardiomyocytes. However, other endogenous mechanisms of cardioprotection of mitoK$_{\text{ATP}}$ activation during IR remain to be elucidated.

Most of the in vitro studies used neonatal cardiac cells or immortal cardiac cell lines such as H9c2, which is physiologically different from adult cardiomyocytes [18]. For example, it is reported that neonatal cardiomyocytes were more resistant to hypoxia in comparison to adult ones [19, 20]. So, it may limit the extrapolation of the research results. We developed an A/R model using adult cardiomyocytes freshly isolated from rat to mimic the IR microenvironment in vivo; after all, MIRI is present almost exclusively in the adult population.

Compared with microarray and PCR-based technologies, digital gene expression (DGE) platform can provide adequate sequence coverage and quantitative accuracy to capture subtle changes resulting from mitoK$_{\text{ATP}}$ opening. In this study, a molecular and bioinformatic pipeline permitted comprehensive analysis of the myocardial mRNA expression. Next-generation sequencing technology was employed and the impact of mitoK$_{\text{ATP}}$ on the myocardial transcriptome signature of MIRI was explored to crystallize cardioprotective effects of mitoK$_{\text{ATP}}$.

2. Materials and Methods

2.1. Experimental Animals. Male Sprague-Dawley rats (250–300 g, 16–20 weeks) were provided by the Third Military Medical University (Chongqing, China) and maintained in specific pathogen free (SPF) animal facility in Zunyi Medical College under standardized conditions with 12 h light/dark cycles and free access to rat chow and water. All experimental procedures were performed according to the "Guide for the Care and Use of Laboratory Animals” in China (no. 14924, 2001) and approved by the Experimental Animal Care and Use Committee of Zunyi Medical College.

2.2. Isolation of Adult Cardiomyocytes. Rats were anesthetized with sodium pentobarbital (60 mg/kg, combined with 250 U/kg heparin, peritoneal injection). When rats had been successfully anesthetized, the chest cavity was opened and the heart excised rapidly. Ventricular cardiomyocytes were obtained by enzymatic digestion as previously described [24], with some necessary modification. Briefly, hearts were retrogradely perfused with 0.1% type 2 collagenase (Sigma, USA) at constant pressure (9 mL/min/g) on a Langendorff apparatus (Alcott Biotech, China); then the ventricle was scissored out and digested by type 2 collagenase solution in a beaker with manually shaking. Cells were filtered through a piece of gauze and washed 5 times to get rid of collagenase. Cardiomyocytes from one heart were evenly titrated into four 60 mm laminin-precovered Petri dishes. Three mL serum free modified M199 medium (Hyclone, USA, with 2 mM carnitine, 2 mM glutamine, 5 mM taurine, 5 mM creatine, and 0.8 mM EGTA) was added. After 3 hours’ incubation, the medium was replaced to get rid of noncardiomyocytes. Cell quality was confirmed with trypan blue exclusion test.

2.3. Anoxia/Reoxygenation and DZ Postconditioning in Adult Rat Cardiomyocytes. For each test, the 4 Petri dishes were placed in normoxia incubator for 20 hours before being randomly distributed to 4 groups: Control (Con), anoxia/reoxygenation (A/R), diazoxide (DZ), and DZ + blocker 5-hydroxydecanote (5-HD) (DZ5HD). Cardiomyocytes of Con were continuously cultured in normoxia environment for 105 min. Medium of A/R group was replaced with N$_2$ bubbled (95% N$_2$, 5% CO$_2$) modified M199 at the 40th min and then replaced with O$_2$ bubbled modified M199 at 45th and 50th min. Medium of DZ group was replaced with N$_2$ bubbled modified M199 at the 40th min; at 45th min, medium was replaced with O$_2$ bubbled modified M199 containing 50 μM DZ and at the 50th min it was replaced with O$_2$ bubbled modified M199 to remove DZ. Medium of DZ5HD group was replaced with N$_2$ bubbled modified M199 at 40th min containing 100 μM 5-HD; at 45th min, it was replaced with O$_2$ bubbled modified M199 containing 50 μM DZ and then replaced with O$_2$ bubbled modified M199 to remove DZ at 50th min.

![Figure 1: Illustration of the experimental A/R model protocols. Cardiomyocytes were cultured for 20 hours in normoxia incubator. Petri dishes were randomly distributed to 4 groups. Cardiomyocytes of Con were continuously cultured in normoxia environment for 105 min. Medium of A/R group was replaced with N$_2$ bubbled (95% N$_2$, 5% CO$_2$) modified M199 at the 40th min and then replaced with O$_2$ bubbled modified M199 at 45th and 50th min. Medium of DZ group was replaced with N$_2$ bubbled modified M199 at the 40th min; at 45th min, medium was replaced with O$_2$ bubbled modified M199 containing 50 μM DZ and at the 50th min it was replaced with O$_2$ bubbled modified M199 to remove DZ. Medium of DZ5HD group was replaced with N$_2$ bubbled modified M199 at 40th min containing 100 μM 5-HD; at 45th min, it was replaced with O$_2$ bubbled modified M199 containing 50 μM DZ and then replaced with O$_2$ bubbled modified M199 to remove DZ at 50th min.](image-url)

2.4. Intracellular Free Calcium ([Ca$^{2+}$]$_i$) Test. At the end of reoxygenation, [Ca$^{2+}$]$_i$ was detected as previously reported.
Oxidative Medicine and Cellular Longevity

[25]. Briefly, M199 was removed; cardiomyocytes of 4 groups were washed twice with PBS and loaded with Fluo-3 AM (Biotium, USA) at a final concentration of 10 μM and incubated for 30 min at 37°C in O₂/CO₂ incubator. The solution containing the Ca²⁺ probe was removed and cells were washed twice again with PBS. The average fluorescence intensity of [Ca²⁺], concentration in labeled cells was detected under a laser scanning confocal microscope (TCS SP2 AOBS, Leica, Germany). The wavelength of excitation was set at 488 nm and the emission wavelength was 525 nm for Fluo-3 fluorescence reading. More than 20 cells from each group were randomly chosen for data analysis; their outlines were circled out and the fluorescence density of Fluo-3 was calculated with Leica confocal software (Leica, Germany).

2.5. Cell Viability Detection. Adult cardiomyocytes’ viability was detected with Cell Counting Kit-8 (CCK-8, Beyotime, China) in accordance with the manufacturer’s instructions. The same amount of cells was seeded into 24-well plates. At the end point of reoxygenation, 30 μL WST-8 solution was added into M199 to form a 3% WST-8 final concentration. Cells were incubated for 1 h before the mixture’s OD value was detected at 450 nm wavelength. The replicate size was 6 for each group.

2.6. RNA Extraction. At the end of reoxygenation (see Section 2.3), cardiomyocyte samples (3 replicates for 4 groups) were homogenized in TRIzol reagent (Invitrogen, USA) and vortexed with chloroform. The mixture was pre-treated at room temperature for 2 min and then centrifuged at 12000 × g at 4°C. The aqueous phase was mixed with 100% ethanol and then filtered with a Qiagen RNeasy column. Subsequent steps for extraction of total RNAs were carried out as the Qiagen RNeasy kit (Qiagen, Germany) instructions described.

2.7. Tag Library Construction. The tag-seq library was constructed in accordance with the manufacturer’s workflow as previously described [26]. Briefly, 6 mg extracted total RNA was used for mRNA capture with magnetic Oligo (dT) beads. Then cDNA was synthesized and the bead-bound cDNA was subsequently digested with NlaIII. Fragments attached to Oligo (dT) beads were washed away. GEX NlaIII adapter was ligated to the free 5’ end of the digested bead-bound cDNA fragments. Individual cDNA libraries were PCR amplified and purified on a 6% acrylamide gel. Attached DNA fragments were used to create a sequencing flow cell with millions of clusters, which contained about 1000 copies of the templates. Templates were sequenced by the Illumina HiSeq 2500 equipment using the four-color DNA sequencing-by-synthesis (SBS) technology. Each lane generated millions of raw reads.

2.8. Data Processing and Statistical Analysis. To obtain high quality and reliable data, raw reads were filtered to remove potentially erroneous reads. Briefly, the 3’ adaptor sequences were trimmed, low-quality tags containing N were abandoned, and small tags and only 1 copy tag were removed before obtaining the clean reads. After filtering, all reads were annotated to Rat Genome V3.4 Assembly (http://rgd.mcw.edu/). All the clean reads were mapped to the reference database; the unambiguous tags were annotated. Copy number of the clean tags of each gene was normalized with the RPKM (reads per kilobase of exon per million mapped reads) method [27] to get the final gene expression.

2.9. Identification of DEGs. According to the method by Tarazona et al. [28], the NOISeq-real algorithm was employed to determine the Q value (corresponding to the P value in differential gene expression detection) and screen genes [29, 30] differentially expressed between Con and A/R, A/R and DZ, and DZ and DZ5HD. In the present study, we considered a gene differentially expressed if the Q value was more than 0.8.

2.10. Gene Annotation with Gene Ontology and KEGG Pathway. GO (http://www.geneontology.org) provides a dynamic, controlled vocabulary. It comprises 3 independent ontologies: Biological Process, Molecular Function, and Cellular Component, each of which contains hundreds of terms. These terms reflect our understanding of the gene function.

KEGG Pathway database is for systematical analysis of gene functions, linking genomic information with higher order functional information. It provides an indication of the main biochemical and signal transduction pathways that DEGs are involved in.

Finally, the DEGs were enriched with GO (into ontologies and terms) and KEGG Pathway database.

2.11. RT-qPCR Analysis. Twenty-five DEGs were randomly selected for real-time quantitative PCR (RT-qPCR). The total RNA used for sequencing was reused to validate DGE sequencing. 500 ng RNA was reverse-transcribed into cDNA using a cDNA synthesis kit (Takara, Japan) in a final volume of 10 μL according to the manufacturer’s protocol. RT-qPCR was performed with the CFX Connect Real-Time system (Bio-Rad, USA) using a SYBR green PrimeScript RT kit (Perfect Real Time, Takara, Japan) based on the manufacturer’s instructions. The PCR conditions included predenaturing at 95°C for 30 s followed by 40 cycles of denaturation at 95°C for 10 s and combined annealing/extension at 58°C for 30 s. All the mRNA expression levels were calculated based on the comparative quantification method (2−ΔΔCT). The β-actin gene was used as an internal control. The primer sequences were listed in Table 4.

2.12. ATP Quantitation in Cardiomyocytes. At the end of reoxygenation, the cardiomyocytes were scraped off and centrifuged at 1000 × g for 5 min; the supernatant (M199 medium) was abandoned. 1 mL precooled 0.4 M HClO₄ was added into the pellet and followed by ultrasonication and centrifugation at 10000 × g for 20 min. The supernatant was collected and its pH was adjusted to 6.0 to 7.0 with 0.7 mL 1 M K₂HPO₄ before centrifugation again at 10000 × g for another 20 min. All the above-mentioned procedures were conducted at 4°C. The supernatant was filtered through 0.22 μm
membrane before high performance liquid chromatography (HPLC) analysis. The chromatographic conditions were as follows: work station: LC 20A (Shimadzu, Japan); column: WondaSil C18-WR (150 mm × 4.6 mm, id = 5 μm; GL Sciences, Japan); column temperature: 25 °C; mobile phase: buffered phosphate at pH 7.0; flow rate: 1 mL/min; detection wavelength: 254 nm; sample size: 10 μL. The ATP peaks of samples were determined based on the standard curve and regression equation from ATP standard’s concentration and peak area. Protein content was measured by using the same sample. ATP level of each sample is normalized to protein content.

2.13. Statistical Analysis. The quantitative data were expressed as mean ± SD. For experiments of cardiomyocytes of the four groups, one-way analysis of variance (ANOVA) was performed; LSD or Dunnett’s T3 method was used to make multiple comparisons. A P value of less than 0.05 was considered to be statistically significant. All data analyses were carried out using SPSS v.19.0 (IBM, USA).

3. Results

3.1. Isolated Adult Rat Cardiomyocytes. A high percentage (70–80%) of rod-shaped adult cardiomyocytes with clear striations and sharp outlines without visible vesicles were obtained with our method (Figure 2(a)).

3.2. \([Ca^{2+}]_i\) and Cell Viability Detection. We used Fluo-3 AM to examine \([Ca^{2+}]_i\) mobilizations in cardiomyocytes. In Con group, the level of \([Ca^{2+}]_i\) was the lowest. Compared with Con, \([Ca^{2+}]_i\) increased significantly in A/R (P < 0.05). After the applying of DZ, \([Ca^{2+}]_i\) fluorescence decreased dramatically (P < 0.05) compared with A/R while there was an apparent increase (P < 0.05) in D2Z5HD compared with DZ (Figures 2(b) and 2(c)). It indicated that DZ strongly inhibited the \([Ca^{2+}]_i\) levels in adult rat cardiomyocytes.

Cardiomyocytes in A/R group possessed lower level of cell viability (P < 0.05) when compared with Con. DZ group contained higher level of cell viability (P < 0.05) when compared with A/R group, while D2Z5HD group showed lower level of cell viability (P < 0.05) when compared with DZ group (Figure 2(d)).

3.3. Quality Evaluation of DGE Reads. A summary of the DGE reads and their mapping to the rat genome database is presented in Supplementary Table 1 available online at http://dx.doi.org/10.1155/2014/756576. For each group, more than 4.4 million clean reads were sequenced. Low-quality reads accounted for no more than 1.6% and modified Q30 bases rate no less than 97% in all the 12 libraries (Supplementary Table 1). Besides, perfect matched reads accounted for 60% and unique matched reads occupied more than 70% of all reads mapping to rat genome (Table 1), which revealed that the sample preparation and the sequencings were in perfect condition.

3.4. Sequencing Saturation Analysis. Samples with replicates of sequencing, sequencing saturation analysis can be performed to test whether the detected genes’ percent increased with total reads number. As shown in Supplementary Figure 1, for 3 replicates of 4 groups, when the total tag number came to 3 million, the genes number started to level out. When the total tag number reached 4 million, gene number inclined to stabilization. It suggested that no more distinct genes would be identified when the total clean reads reached a certain number. For all of the 12 libraries, there were more than 4.4 million clean reads (Supplementary Table 1), which indicated that the deep sequencing results were comprehensive and saturated.

3.5. DEGs between Groups. All genes annotated to the rat genome (Supplementary Excel 1) were analyzed for an evidence of differential expression. A detailed description of DEGs between two groups was presented in Supplementary Excel 2 (Con versus A/R), Excel 3 (A/R versus DZ), and Excel 4 (DZ versus DZ5HD). Those genes were to some extent differentially expressed; they were considered significant with a Q value more than 0.8. A list of the top 10 DEGs between two groups was shown in Table 2. In these genes, Mt-nd6, Acd1l, and Idh2 are energy metabolism correlated and their expression status is listed in Table 3.

3.6. RT-qPCR Analysis. To confirm the DEGs revealed by the Illumina sequencing, 25 genes were randomly selected (Table 4) and assayed by SYBR green based RT-qPCR (Figure 3). Except Cya5, Idh3B, Mgst3, and Pdk4, 21 out of the 25 genes were expressed well in accordance with the results from Illumina sequencing (Table 4).

3.7. GO Enrichment Analysis. Ontology and term enrichment of DEGs in GO is listed in Figure 4. GO enrichment showed many of the DEGs from Con versus A/R (Figure 4(a)), A/R versus DZ (Figure 4(b)), and DZ versus DZ5HD (Figure 4(c)) participating in the Biological Process ontology. Histogram presentation of Gene Ontology functional classification and DEGs’ enrichment is shown in Figures 4(d)–4(f) (id) Con versus A/R; (e) A/R versus DZ; (f) DZ versus DZ5HD). The significantly enriched (corrected P < 0.05) terms for Con versus A/R (Supplementary Table 2), A/R versus DZ (Supplementary Table 3), and DZ versus DZ5HD (Supplementary Table 4) also listed.

3.8. Pathway Analysis. KEGG Pathway provides an indication of the main biochemical and signal transduction pathways that DEGs are involved in. Pathway enrichment for Con versus A/R, A/R versus DZ, and DZ versus DZ5HD were displayed in Supplementary Tables 5–7. For Con versus A/R, A/R versus DZ, and DZ versus DZ5HD, there were 40, 48, and 37 pathways highly enriched (P < 0.01, Q < 0.05), respectively.

In all the pathways, Metabolic Process was the DEGs most enriched one. It is not difficult to notice that many energy metabolism correlated pathways, such as fatty acid
Table 1: Summary of DGE profile and reads' mapping to the rat genome.

| Library number | Total reads (%) | Total base pair (%) | Total mapped reads (%) | Perfect match (%) | ≤2 bp mismatch (%) | Unique match (%) | Multiposition match (%) | Total unmapped reads (%) |
|----------------|-----------------|---------------------|------------------------|------------------|---------------------|-------------------|-------------------------|--------------------------|
| Con-1          | 4350000, 100%   | 213120000, 100%     | 3690000, 84.92%        | 2690000, 61.92%  | 1000000, 23.00%    | 3470000, 79.81%    | 220000, 5.10%            | 650000, 15.08%           |
| Con-2          | 5180000, 100%   | 253940000, 100%     | 4130000, 79.86%        | 3110000, 60.19%  | 1010000, 19.66%    | 3750000, 72.47%    | 380000, 7.38%            | 1040000, 20.14%          |
| Con-3          | 4760000, 100%   | 233230000, 100%     | 3890000, 81.74%        | 2840000, 59.76%  | 1040000, 21.98%    | 3550000, 74.67%    | 330000, 7.07%            | 860000, 18.26%           |
| A/R-1          | 5310000, 100%   | 260380000, 100%     | 4280000, 80.55%        | 3250000, 61.34%  | 1020000, 19.21%    | 3890000, 73.21%    | 390000, 7.34%            | 1030000, 19.45%          |
| A/R-2          | 4600000, 100%   | 225450000, 100%     | 3760000, 81.85%        | 2800000, 61.07%  | 950000, 20.78%     | 3440000, 74.81%    | 320000, 7.03%            | 830000, 18.15%           |
| A/R-3          | 5040000, 100%   | 246860000, 100%     | 4180000, 83.12%        | 3050000, 60.64%  | 1130000, 22.48%    | 3810000, 75.66%    | 370000, 7.46%            | 850000, 16.88%           |
| DZ-1           | 5110000, 100%   | 250260000, 100%     | 4200000, 82.42%        | 3180000, 62.28%  | 1020000, 20.15%    | 3860000, 75.71%    | 340000, 6.72%            | 890000, 17.58%           |
| DZ-2           | 5010000, 100%   | 245250000, 100%     | 4080000, 81.52%        | 3050000, 60.94%  | 1030000, 20.58%    | 3720000, 74.32%    | 360000, 7.20%            | 920000, 18.48%           |
| DZ-3           | 4900000, 100%   | 240220000, 100%     | 4060000, 82.84%        | 2980000, 60.93%  | 1070000, 21.91%    | 3680000, 75.09%    | 380000, 7.76%            | 840000, 17.16%           |
| DZ5HD-1        | 4900000, 100%   | 240100000, 100%     | 3940000, 80.58%        | 2960000, 60.58%  | 980000, 20.01%     | 3620000, 73.89%    | 320000, 6.69%            | 950000, 19.42%           |
| DZ5HD-2        | 4720000, 100%   | 231050000, 100%     | 3770000, 80.12%        | 2860000, 60.80%  | 910000, 19.32%     | 3390000, 71.96%    | 380000, 8.16%            | 930000, 19.88%           |
| DZ5HD-3        | 4470000, 100%   | 218750000, 100%     | 3670000, 82.37%        | 2680000, 60.21%  | 980000, 22.16%     | 3350000, 75.16%    | 320000, 7.21%            | 780000, 17.63%           |
Figure 2: Adult rat cardiomyocytes and their status tests after mitoK<sub>ATP</sub> opening. (a) Light microscopic morphology of freshly isolated adult cardiomyocytes. They were rod-shaped, with sharp outlines and clear cross striations. (b-c) The effect of DZ and 5HD on the [Ca<sup>2+</sup>]<sub>i</sub> in adult rat cardiomyocytes. At the end point of reoxygenation, cells of Con, A/R, DZ, and DZ5HD group were pretreated with 10 μM Fluor-3-AM and incubated for 60 min at 37°C and measured with a confocal laser microscope. (b) The [Ca<sup>2+</sup>]<sub>i</sub> fluorescence image of cardiomyocytes in four groups. (c) The [Ca<sup>2+</sup>]<sub>i</sub> fluorescence intensity comparison. [Ca<sup>2+</sup>]<sub>i</sub> in A/R group was increased compared with the Con. Applying of DZ reduced the fluorescence intensity. After 5-HD administration, fluorescence intensity increased. (d) Cell viability test with CCK-8 kit. At the end point of reoxygenation, 30 μL CCK-8 was added into M199 to form a 3% CCK-8 resulting solution. Cells were incubated for 1 h before the mixture’s OD value was detected at 450 nm. Cardiomyocytes of A/R group possessed lower level of cell viability when compared with Con. DZ group contained higher level of cell viability when compared with A/R group. Cells in DZ5HD showed the lowest level of cell viability in the 4 groups. Data are mean ± SD. Replication number for each group is marked on the columns. *P < 0.05.

Table 2: Top 10 DEGs from Con versus A/R, A/R versus DZ, and DZ versus DZ5HD.

| Number | Gene name   | Con versus A/R log<sub>2</sub>Ratio (A/R/Con) | Q value | A/R versus DZ log<sub>2</sub>Ratio (DZ/A/R) | Q value | DZ versus DZ5HD log<sub>2</sub>Ratio (DZ5HD/DZ) | Q value |
|--------|-------------|---------------------------------------------|---------|--------------------------------------------|---------|-----------------------------------------------|---------|
| 1      | Pdlim2      | 4.95                                        | 0.84    | 5.02                                       | 0.95    | 4.22                                         | 0.92    |
| 2      | MT-ND6      | −4.94                                       | 0.94    | 4.92                                       | 0.95    | MT-ND6                                       | −3.95   | 0.91   |
| 3      | Aldha7      | −4.92                                       | 0.82    | 4.87                                       | 0.94    | Atf4                                         | 3.92    | 0.91   |
| 4      | Idh2        | −4.83                                       | 0.94    | Mdh1                                       | 4.84    | Ldhb                                         | −3.85   | 0.91   |
| 5      | Uba52       | −4.71                                       | 0.93    | Mdh2                                       | 4.73    | Chu                                          | 3.84    | 0.90   |
| 6      | Mdh2        | −4.68                                       | 0.93    | Aldh16a1                                   | 4.67    | Idh2                                         | −3.75   | 0.90   |
| 7      | Podn1l      | −4.65                                       | 0.80    | Podn1l                                     | 4.61    | Ankr1                                        | 3.74    | 0.90   |
| 8      | Mdh1        | −4.63                                       | 0.93    | Omg                                        | 4.60    | 0.82                                         | Podn1l  | −3.73   | 0.80   |
| 9      | RGD13I1224  | −4.59                                       | 0.81    | MT-ND6                                     | 4.56    | Acadl                                        | −3.69   | 0.90   |
| 10     | Acadl       | −4.58                                       | 0.93    | Uba52                                      | 4.56    | RGD13I1224                                   | −3.66   | 0.81   |
Table 3: Three energy metabolism related DEGs.

| Gene name    | Gene description                  | Con versus A/R | A/R versus DZ | DZ versus DZ5HD |
|--------------|-----------------------------------|----------------|---------------|-----------------|
| MT-ND6       | NADH dehydrogenase subunit 6 (mitochondron) | log₂(Q) = −4.94, Q = 0.94 | log₂(Q) = 4.56, Q = 0.93 | log₂(Q) = −3.95, Q = 0.91 |
| Idh2         | Isocitrata dehydrogenase 2 (NADP+), mitochondrial | log₂(Q) = −4.83, Q = 0.94 | log₂(Q) = 5.02, Q = 0.95 | log₂(Q) = −3.75, Q = 0.90 |
| Acadl        | Acyl-Coa dehydrogenase, long chain | log₂(Q) = −4.58, Q = 0.93 | log₂(Q) = 4.87, Q = 0.94 | log₂(Q) = −3.69, Q = 0.90 |

MitoK\textsubscript{ATP} opening or closing in cultured adult rat cardiomyocytes significantly resulted in gene expression change. Many of the genes were energy related. Metabolic Process was the DEGs most enriched GO ontology and energy metabolism correlated pathways were highly enriched too. We could not help doubting that mitoK\textsubscript{ATP} might have interfered with the energy metabolism and we confirmed that by directly measuring ATP content of four groups at the end of reoxygenation.

Three energy metabolism correlated genes, Mt-nd6, Idh2, and Acadl, were all upregulated (A/R versus DZ). Mt-nd6 encodes NADH-quinone oxidoreductase (complex I) subunit 6 in mammal. In the respiratory chain, complex I is responsible for the oxidation of NADH and contributes to the formation of the proton gradient which drives ATP synthesis and passes electrons to ubiquinone [31]. Ischemia-reperfusion injury was characterized by decreased complex I respiration [32]. In this study, expression of Mt-nd6 decreased after A/R treatment, while it was upregulated tremendously in DZ compared with A/R. Complex I is extremely susceptible to oxidative damage and subsequently produces more ROS [33], leading to extensive mitochondrial dysfunction and the depletion of ATP. MitoK\textsubscript{ATP} opening by DZ increased Mt-nd6 expression, which might have contributed to ATP synthesis and resulted in its myocardial protection.

Idh2 encodes isocitrate dehydrogenase in mitochondria. In present study, expression of Idh2 varied: Con versus A/R downregulated; A/R versus DZ upregulated; DZ versus DZ5HD downregulated. Isocitrate dehydrogenase is the rate-limiting enzyme of TCA cycle, which catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Isocitrate dehydrogenase plays a role in intermediary metabolism and energy production. It had been reported that isocitrate dehydrogenase activity increased at the ischemia region when heart underwent ischemia [34, 35]; the authors deemed the increase that came from the increased need of energy.

Long Chain Acyl-Coa Dehydrogenase (Acadl) encodes long chain acyl-Coa dehydrogenase, which catalyzes the $\alpha$- and $\beta$-dehydrogenation of acyl-Coa esters in fatty acid metabolism. It is the first rate-limiting enzyme in fatty acid $\beta$-oxidation reaction [36]. In present study, Acadl was downregulated after A/R, upregulated when mitoK\textsubscript{ATP} opened, and downregulated again when mitoK\textsubscript{ATP} was blocked by 5-HD. In physiological state, 60–70% of the total energy the heart needs comes from fatty acid $\beta$-oxidation [37]. In the ischemic condition, FAO is more indispensable. Ito et al. [38] demonstrated that high levels of fatty acids in the
Table 4: Genes selected for RT-qPCR confirmation.

| Gene name | Forward Primer sequences (5’ to 3’) | Reverse Primer sequences | Reads number (RPKM, mean from 3 sequencings) |
|-----------|-----------------------------------|--------------------------|---------------------------------------------|
|           |                                   |                          | Con  | A/R | DZ  | DZ5HD |
| Acdl      | GGAATGAAAGCAGCAGACAG              | TCAACTGACTTCAGAGCAAGGAA | 421.61 | 17.57 | 515.82 | 39.71 |
| Aldoa     | GGTGGTTTGTTGGAATTAAGGT            | ATGGCGAGGAGCGAGGAGTA     | 1171.38 | 1358.29 | 1300.62 | 121.90 |
| Ankrd1    | AAAATCGCTGCTGACACACACG            | ACCGAGTCTCTAGAGAGCGCC   | 2875.32 | 3262.76 | 215.95  | 2890.14 |
| Cat       | GGCCACCTTTGACAGAGGCGGGGGC         | CTTGAGAATGGCGAGAGCA     | 143.64  | 11.32  | 149.61  | 152.13 |
| Ckm       | AACCCACAGAAAGCATAAGACCC          | CTTCCACGGACAGCTTCTCTACA | 862.02  | 929.51  | 903.35  | 139.07 |
| Clu       | ACTCGAGGACCTCTCTCTGT             | TTTCTGCTGATTTCTCTCTACG  | 1009.00 | 1068.16 | 73.26   | 1050.66 |
| Cycs      | AAAGCAGACTGACAGCAGAAGCCACTTCC   | GTGATACCTTTGTCTTTTGCCAT | 230.49  | 289.74  | 129.06  | 283.52 |
| Epas1     | ACCCTGCCAGGACACATCTACC           | ACTTGCCACTGACAGCCCTTT   | 10.16   | 10.53   | 10.68   | 1.89 |
| Got2      | GGGAGCAGCTTGTATTTTGATAGG        | CAGAAGACATCTCGGCACTAAT  | 241.93  | 277.84  | 54.72   | 275.22 |
| Gpi       | ACCACCGGAGACATCACCAAC           | CTACCAATCTCCAGAAPCTGAAAC | 137.57 | 10.77 | 146.16 | 141.82 |
| Gsr       | GTTTGGTTTTCTCTGTCTTGGG          | GAGGAATCTCTGATATTCTCTAGG | 15.80   | 21.76   | 4.91    | 22.58 |
| Hspa5     | ACACCTGGTATTGAAACTTGAGG          | CTTGATTGTACGGTGAGCTG    | 132.59  | 171.78  | 157.12  | 27.08 |
| Idh2      | CACATACGATTTGGAGACAC          | CCTCTCGAGACGAGGACTTACA | 718.92  | 25.15   | 816.33  | 60.47 |
| Idh3B     | ATTCGAGAAACAGACAGAGGGAGGATG    | CTTCGAGTACTTGTCTGAGTGACG | 17.23   | 210.25  | 28.79   | 205.45 |
| Ldhb      | ACCAGAGCTGAAGAGCATG            | TGAGCTAGCTAGAAAGCCAGAA | 1337.06 | 1599.30 | 1535.85 | 106.07 |
| Mdh1      | TCTCCCTCGCATGACTCACAG         | TAGTCGAGCAGACTAACAAGCT | 445.93  | 1792    | 513.76  | 130.68 |
| Mgs1      | AAAGCGCGCAAGAAGTAAAGGT          | CAGGTTAGAGAAGATAGGAGAGG | 175.29  | 183.50  | 178.22  | 75.55 |
| Mif       | TATACGACATTGACGACAGT         | TCAACCATTGCTTCGAGGACC   | 75.60   | 19.21   | 82.05   | 22.40 |
| Oxc1      | ATTGGAGCATGCTTTTGCTCTC          | TGTTGCTTCTCTCTGCTCTTCTT | 224.68 | 10.00 | 303.23 | 43.54 |
| Pdk4      | CAAAGCTCAGCTTCAACATTTCA        | AACACAAGATTCAACACACATTCA | 184.97 | 14.36 | 193.38 | 32.08 |
| Psmd7     | AAGACGACCTGAGAAGGAGGA         | AAGGTTGAGCGAGGAGCAGAG   | 74.87   | 82.47   | 13.07   | 59.27 |
| Sdha      | CTCCTCTCTACCCGCTCAGATC        | TGTGTAAGGAATCATCAGCTTCCAG | 209.87 | 17.69 | 263.44 | 254.47 |
| Sdhb      | TCAAGCGAGGCAAGGACGCT         | GTGATAGGTAATCAAGCTAGGGA | 378.70  | 425.40  | 36.17   | 49.09 |
| Sod1      | GCTGCTGACTGCTTTGCTCTG          | CTGTTGCAAGGCTTCCCTCTTCT | 186.25  | 21.37   | 199.90  | 198.85 |
| Uba52     | ACCCTTGCGACTCAACCTCCA         | TGATCTTCTGGGCAAGCTGACGA | 618.42  | 23.57   | 556.13  | 51.39 |
Figure 4: Continued.
perfusate were capable of enhancing posts ischemic energy production and increasing contractile function. That study provided evidence that, in heart with limited oxidative capacity, increasing exogeneous energy substrate supply and boosting FAO generated more ATP and quickly normalized energy production. From what is mentioned above, mitoK<sub>ATP</sub> opening may alleviate the energy depletion when adult cardiomyocytes underwent A/R injury by boosting the fatty acid β-oxidation.

6 energy correlated pathways, Peroxisome pathway, PPAR signaling pathway, citrate cycle (TCA cycle) pathway, fatty acid metabolism pathway, and proteasome pathway were DEGs significantly enriched (P < 0.01).

TCA cycle and fatty acid metabolism directly generate energy. 7 DEGs from Con versus A/R were enriched in TCA cycle pathway. They were all downregulated after A/R injury. When mitoK<sub>ATP</sub> was open, all of them were upregulated. It is obvious that A/R suppressed TCA cycle. This could be one of the reasons why A/R decreased ATP content. We could see that DZ saved TCA cycle. 8 DEGs from Con versus A/R and 14 DEGs from A/R versus DZ, including Acadl, were enriched in fatty acid metabolism pathway. It seemed that A/R suppressed these two pathways and mitoK<sub>ATP</sub> reinforced them.

Peroxisome proliferator-activated receptors (PPARs), especially PPAR-α, are sensitive to fatty acids and their derivatives. They are also ligand-activated transcription factors regulating cardiac FAO and energy homeostasis [39, 40]. PPAR-α is expressed highly in the heart and evidence had showed that PPAR-α was involved in the regulation of numerous genes encoding FAO enzymes [41]. Overexpression of PPAR-α and its target metabolic genes promoted FAO as a source of energy under conditions of acute IR [42, 43]. Besides its well-known action on cardiac energy metabolism and lipid homeostasis, emerging evidence indicated that administration of PPAR-α synthetic ligands was myocardial protective in an IR setting, as manifested by improved posts ischemic recovery of contractile function and reduced infarct size in both in vivo and ex vivo models [42, 44]. Mice overexpressing PPAR-α in heart displayed increased FAO rates, accumulated triacylglycerides, and decreased glucose metabolism, and they eventually developed cardiomyopathy [45, 46]. Not surprisingly, mice lacking PPAR-α had elevated free fatty acid levels as a consequence of inadequate FAO, rendering them hypoglycemic as a result of their reliance on glucose [47]. In present study, although PPAR-α gene did not change after mitoK<sub>ATP</sub> opening, 17 DEGs from A/R versus DZ were enriched in peroxisome pathway (P = 1.3 x 10^-7) and 16 DEGs significantly enriched in PPAR signaling pathway (P = 9.9 x 10^-7). 12 DEGs from DZ versus DZ5HD were enriched in (P = 1.1 x 10^-6) peroxisome pathway and 14 enriched in PPAR signaling pathway (P = 2.4 x 10^-5). Nevertheless, to test the

---

**Figure 4: Ontology and term enrichment of DEGs in Gene Ontology.** (a–c): Ontology enrichment for Con versus A/R, A/R versus DZ, and DZ versus DZ5HD. Most of the DEGs from Con versus A/R (2056 DEGs, 48.86%), A/R versus DZ (2955, 50.2%), and DZ versus DZ5HD (2224, 49.59%) participated in the Biological Process ontology. (d–f): Histogram presentation of Gene Ontology functional classification and DEGs’ enrichment ((d) Con versus A/R; (e) A/R versus DZ; (f) DZ versus DZ5HD). The results are summarized in three main categories: Biological Process, Cellular Component, and Molecular Function. The y-axis on the right is the number of DEGs in a category. The y-axis on the left is the percentage of a specific category of genes in the main category. For significantly enriched terms (Con versus A/R, A/R versus DZ, and DZ versus DZ5HD), see Supplementary Tables 2–4.
Table 5: DEGs highly enriched and energy related pathways.

| Pathway name | Pathway ID | Con versus A/R | A/R versus DZ | DZ versus DZHD |
|--------------|------------|----------------|---------------|---------------|
|              |            | DEGs with pathway annotation (335) | DEGs with pathway annotation (467) | DEGs with pathway annotation (361) |
|              |            | P value | Q value | P value | Q value | P value |
| Proteasome   | ko03050    | 14 (4.18%) | 1.605768e − 11 | 2.141436e − 16 | 1.912420e − 13 | 1.605768e − 11 |
| Fatty acid metabolism | ko00071 | 8 (2.39%) | 4.058827e − 05 | 2.210798e − 09 | 9 (2.49%) | 4.058827e − 05 |
| Peroxisome   | ko04146    | 13 (3.88%) | 2.092866e − 05 | 1.297428e − 07 | 12 (3.32%) | 2.092866e − 05 |
| PPAR signaling pathway | ko0320 | 14 (4.18%) | 4.722899e − 07 | 9.881599e − 07 | 14 (3.88%) | 4.722899e − 07 |
| TCA cycle    | ko00020    | 7 (2.09%) | 4.474838e − 06 | 1.954397e − 13 | 12 (3.32%) | 4.474838e − 06 |

aPathway analysis based on KOBAS server 2.0 [21, 22].
bP value in hypergeometric test; P < 0.01 is considered as DEGs highly enriched.
cThe Q value is similar to the well-known P-value, except it is a measure of significance in terms of the false discovery rate rather than the false positive rate [23].
The ubiquitin proteasome system (UPS) degrades targeted abnormal and most normal proteins in cells. Most degradation via the UPS is ATP-dependent. This process involves ubiquitin ligases E1, E2, and E3, which function in concert with chaperones to identify and ubiquitinate appropriate target proteins [48–50]. Then the resulting polyubiquitinated proteins are transferred to the 26S proteasome, where they are degraded into peptides and ubiquitin. Proteasome pathway enriched 14 DEGs from Con versus A/R; 13 DEGs were downregulated in A/R group while 7 DEGs upregulated after mitoK<sub>ATP</sub> opening. It is obvious that A/R induced the downregulation of UPS and mitoK<sub>ATP</sub> opening reactivated it. Proteasome that functioned insufficiently had been observed most consistently in MIRI [51, 52]. Such studies supported the hypothesis that IR decreased proteasome activity by reducing ATP levels, as well as oxidative unfolding and damaging proteasome proteins [53]. To test this hypothesis, proteasome gain-of-function or loss-of-function studies in animal models of MIRI were carried out. However, the results showed a paradox: gain-of-function using transgenic mice with increased proteasome activity showed protection from MIRI [54], whereas loss-of-function studies using pharmacological means also revealed protection from MIRI [55–57]. In present study, 13 DEGs were downregulated after A/R (Con versus A/R); this should be a feedback of ATP depletion resulting from A/R. 7 DGEs were upregulated in DZ group (A/R versus DZ); this could be a consequence of ATP recovery after mitoK<sub>ATP</sub> opening.

Energy was so desperately needed in A/R environment that Metabolic Process was the most enriched GO ontology in Con versus A/R, A/R versus DZ, and DZ versus DZ5HD. In addition, energy metabolism related genes and pathways were significantly interfered with each other (Figure 6). UPS is protein related; TCA cycle pathway controls aerobic metabolism of glucose, PPAR-α, and Acadl effect on β-dehydrogenation of acyl-CoA esters in FAO. To sum up, mitoK<sub>ATP</sub> regulated the metabolism of 3 main nutriments: glucose, fatty acid, and protein and kept a balance between energy production and consumption at the setting of A/R in adult cardiomyocytes. Strategies to increase energy supply in MIRI may be a good choice. Metabolism correlated genes and pathway nodes may be promising therapeutic targets. At the same time, we must confess that, to assure the effects of specific gene and signaling pathway mentioned above in MIRI, further gain- or/and loss-of-function studies will be needed.

**Conflict of Interests**

The authors declare that there is no conflict of interests regarding the publication of this paper.

**Authors’ Contribution**

Song Cao and Yun Liu contributed equally to this study.

**Acknowledgment**

This work was supported by grants from Special Scientific Research Fund for Public Welfare, Ministry of Health of China (Grant no. 200802173).
References

[1] R. Bolli, “Preconditioning: a paradigm shift in the biology of myocardial ischemia,” *The American Journal of Physiology—Heart and Circulatory Physiology*, vol. 292, no. 1, pp. H19–H27, 2007.

[2] C. E. Murry, R. B. Jennings, and K. A. Reimer, “Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium,” *Circulation*, vol. 74, no. 5, pp. 1124–1136, 1986.

[3] C. E. Murry, V. J. Richard, K. A. Reimer, and R. B. Jennings, “Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode,” *Circulation Research*, vol. 66, no. 4, pp. 913–931, 1990.

[4] I. Inoue, H. Nagase, K. Kishi, and T. Higuti, “ATP-sensitive K+ channel in the mitochondrial inner membrane,” *Nature*, vol. 352, no. 6332, pp. 244–247, 1991.

[5] K. D. Garlid, P. Paucek, V. Yarov-Yarovoy et al., “Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels: possible mechanism of cardioprotection,” *Circulation Research*, vol. 81, no. 6, pp. 1072–1082, 1997.

[6] Y. Liu, T. Sato, B. O’Rourke, and E. Marban, “Mitochondrial ATP-dependent potassium channels: novel effectors of cardiosertion?” *Circulation*, vol. 97, no. 24, pp. 2463–2469, 1998.

[7] K. D. Garlid, P. Paucek, V. Yarov-Yarovoy, X. Sun, and P. A. Schindler, “The mitochondrial K_{ATP} channel as a receptor for potassium channel openers,” *The Journal of Biological Chemistry*, vol. 271, no. 15, pp. 8796–8799, 1996.

[8] G. J. Gross, “ATP-sensitive potassium channels and myocardial preconditioning,” *Basic Research in Cardiology*, vol. 90, no. 2, pp. 85–88, 1995.

[9] X.-M. Yang, J. B. Proctor, L. Cui, T. Krieg, J. M. Downey, and M. V. Cohen, “Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways,” *Journal of the American College of Cardiology*, vol. 44, no. 5, pp. 1103–1110, 2004.

[10] M. Donato, V. D’Annunzio, G. Berg et al., “Ischemic postconditioning reduces infarct size by activation of A1 receptors and K+ATP channels in both normal and hypercholesterolemic rabbits,” *Journal of Cardiovascular Pharmacology*, vol. 49, no. 5, pp. 287–292, 2007.

[11] J. Mykytenko, J. G. Reeves, H. Kin et al., “Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial K_{ATP} channels during reperfusion,” *Basic Research in Cardiology*, vol. 103, no. 5, pp. 472–484, 2008.

[12] L. Yang and T. Yu, “Prolonged donor heart preservation with pinacidil: the role of mitochondria and the mitochondrial adenosine triphosphate-sensitive potassium channel,” *Journal of Thoracic and Cardiovascular Surgery*, vol. 139, no. 4, pp. 1057–1063, 2010.

[13] T. Yu, X.-Y. Fu, X.-K. Liu, and Z.-H. Yu, “Protective effects of pinacidil hyperpolarizing cardioplegia on myocardial ischemia reperfusion injury by mitochondrial KATP channels,” *Chinese Medical Journal*, vol. 124, no. 24, pp. 4205–4210, 2011.

[14] T. Yu, Z. Yu, X. Liu, S. Yang, and Y. Ye, “Myocardial protection with pinacidil induced hyperpolarized arrest during cardiopulmonary bypass,” *Chinese Medical Journal*, vol. 114, no. 12, pp. 1245–1248, 2001.

[15] A. P. Halestrap, “The regulation of the matrix volume of mammalian mitochondria in vivo and in vitro and its role in the control of mitochondrial metabolism,” *Biochimica et Biophysica Acta (BBA)—Bioenergetics*, vol. 973, no. 3, pp. 355–382, 1989.

[16] E. Belisle and A. J. Kowaltowski, “Opening of mitochondrial K+ channels increases ischemic ATP levels by preventing hydrolysis,” *Journal of Bioenergetics and Biomembranes*, vol. 34, no. 4, pp. 285–298, 2002.

[17] P. P. Dzeja, P. Bast, C. Ozcan et al., “‘Targeting nucleotide-requiring enzymes: implications for diazoxide-induced cardio-protection,” *The American Journal of Physiology—Heart and Circulatory Physiology*, vol. 284, no. 4, pp. H1048–H1056, 2003.

[18] E. A. Konorev, S. Vanamala, and B. Kalyanaraman, “Differences in doxorubicin-induced apoptotic signaling in adult and immature cardiomyocytes,” *Free Radical Biology and Medicine*, vol. 45, no. 12, pp. 1723–1728, 2008.

[19] E. Riva and D. J. Hearse, “Age-dependent changes in myocardial susceptibility to ischemic injury,” *Cardioscience*, vol. 4, no. 2, pp. 85–92, 1993.

[20] I. Ostadalova, B. Ostadal, F. Kolár, J. R. Parratt, and S. Wilson, “Tolerance to ischaemia and ischaemic preconditioning in neonatal rat heart,” *Journal of Molecular and Cellular Cardiology*, vol. 30, no. 4, pp. 857–865, 1998.

[21] C. Xie, X. Mao, J. Huang et al., “KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases,” *Nucleic Acids Research*, vol. 39, no. 2, pp. W316–W322, 2011.

[22] J. Wu, X. Mao, T. Cai, J. Luo, and L. Wei, “KOBAS server: a web-based platform for automated annotation and pathway identification,” *Nucleic Acids Research*, vol. 34, pp. W720–W724, 2006.

[23] J. D. Storey and R. Tibshirani, “Statistical significance for genomewide studies,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 16, pp. 9440–9445, 2003.

[24] M.-J. Son, H. K. Kim, D. T. Thu Huong et al., “Chrysosplenol C increases contraction in rat ventricular myocytes,” *Journal of Cardiovascular Pharmacology*, vol. 57, no. 2, pp. 259–262, 2011.

[25] W.-H. Zhang, S.-B. Fu, F.-H. Lu et al., “Involvement of calcium-sensing receptor in ischemia/reperfusion-induced apoptosis in rat cardiomyocytes,” *Biochemical and Biophysical Research Communications*, vol. 347, no. 4, pp. 872–881, 2006.

[26] L.-D. Tang, X.-M. Wang, F.-L. Jin, B.-L. Qiu, J.-H. Wu, and S.-X. Ren, “De novo sequencing-based transcriptome and digital gene expression analysis reveals insecticide resistance-relevant genes in *Propylaea japonica* (Thunberg) (Coleoptera: Coccinellidae),” *PLoS ONE*, vol. 9, no. 6, pp. e0100946, 2014.

[27] A. Mortazavi, B. A. Williams, K. McCue, L. Schaeffer, and B. Wold, “Mapping and quantifying mammalian transcriptomes by RNA-Seq.” *Nature Methods*, vol. 5, no. 7, pp. 621–628, 2008.

[28] S. Tarazona, F. García-Alcalde, J. Dopazo, A. Ferrer, and A. Conesa, “Differential expression in RNA-seq: a matter of depth,” *Genome Research*, vol. 21, no. 12, pp. 2213–2223, 2011.

[29] J. Durban, A. Pérez, L. Sanz et al., “Integrated ‘omics’ profiling indicates that miRNAs are modulators of the ontogenetic venom composition shift in the Central American rattlesnake, *Crotalus simus simus*,” *BMC Genomics*, vol. 14, article 234, 2013.

[30] Q. Tu, R. A. Cameron, K. C. Worley, R. A. Gibbs, and E. H. Davidson, “Gene structure in the sea urchin *Strongylocentrotus purpuratus* based on transcriptome analysis,” *Genome Research*, vol. 22, no. 10, pp. 2079–2087, 2012.

[31] J. E. Walker, “The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains,” *Quarterly Reviews of Biophysics*, vol. 25, no. 3, pp. 253–324, 1992.

Oxidative Medicine and Cellular Longevity

13
[32] G. Ambrosio, J. L. Zweier, and J. T. Flaherty, “The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion,” *Journal of Molecular and Cellular Cardiology*, vol. 23, no. 12, pp. 1359–1374, 1991.

[33] E. J. Lesniesky, Q. Chen, S. Moghaddas, M. O. Hassan, B. Tandler, and C. L. Hoppel, “Blockade of electron transport during ischemia protects cardiac mitochondria,” *Journal of Biological Chemistry*, vol. 279, no. 46, pp. 47961–47967, 2004.

[34] A. Prasad and A. A. Quyyumi, “Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome,” *Circulation*, vol. 110, no. 11, pp. 1507–1512, 2004.

[35] B. I. Judgutt and G. Savicki, “ATReceptor blockade alters metabolic, functional and structural proteins after reperfused myocardial infarction: detection using proteomics,” *Molecular and Cellular Biochemistry*, vol. 263, no. 1, pp. 179–188, 2004.

[36] K. Bartlett and S. Eaton, “Mitochondrial β-oxidation,” *European Journal of Biochemistry*, vol. 271, no. 3, pp. 462–469, 2004.

[37] H. Bugger and E. D. Abel, “Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome,” *Clinical Science*, vol. 114, no. 3–4, pp. 195–210, 2008.

[38] M. Ito, J. S. Jaswal, V. H. Lam et al., “High levels of fatty acids increase contractile function of neonatal rabbit hearts during reperfusion following ischemia,” *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 298, no. 5, pp. H1426–H1437, 2010.

[39] J. A. Madrazo and D. P. Kelly, “The PPAR trio: regulators of myocardial energy metabolism in health and disease,” *Journal of Molecular and Cellular Cardiology*, vol. 44, no. 6, pp. 968–975, 2008.

[40] Q. Yang and Y. Li, “Roles of PPARs on regulating myocardial energy and lipid homeostasis,” *Journal of Molecular Medicine*, vol. 85, no. 7, pp. 697–706, 2007.

[41] P. M. Barger and D. P. Kelly, “PPAR signaling in the control of cardiac energy metabolism,” *Trends in Cardiovascular Medicine*, vol. 10, no. 6, pp. 238–245, 2000.

[42] T.-L. Yue, W. Bao, B. M. Jucker et al., “Activation of peroxisome proliferator-activated receptor-α protects the heart from ischemia/reperfusion injury,” *Circulation*, vol. 108, no. 19, pp. 2393–2399, 2003.

[43] T. Ravingerová, S. Čarníčka, M. Nemčéková et al., “PPAR-α activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischemia-reperfusion injury: involvement of PI3K-Akt,” *Canadian Journal of Physiology and Pharmacology*, vol. 90, no. 8, pp. 1135–1144, 2012.

[44] N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” *The FASEB Journal*, vol. 16, no. 9, pp. 1027–1040, 2002.

[45] B. N. Finck, X. Han, M. Courtis et al., “A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 3, pp. 1226–1231, 2003.

[46] B. N. Finck, J. L. Lehman, T. C. Leone et al., “The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus,” *Journal of Clinical Investigation*, vol. 109, no. 1, pp. 121–130, 2002.

[47] M. Guerre-Millo, C. Rouault, P. Poulain et al., “PPAR-α-null mice are protected from high-fat diet-induced insulin resistance,” *Diabetes*, vol. 50, no. 12, pp. 2809–2814, 2001.

[48] F. Kriegenburg, L. Ellgaard, and R. Hartmann-Petersen, “Molecular chaperones in targeting misfolded proteins for ubiquitin-dependent degradation,” *FEBS Journal*, vol. 279, no. 4, pp. 532–542, 2012.

[49] X. Wang and J. Robbins, “Heart failure and protein quality control,” *Circulation Research*, vol. 99, no. 12, pp. 1315–1328, 2006.

[50] M. S. Willis, W. H. D. Townley-Tilson, E. Y. Kang, J. W. Homeister, and C. Patterson, “Sent to destroy: the ubiquitin proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease,” *Circulation Research*, vol. 106, no. 3, pp. 463–478, 2010.

[51] A.-L. Bulteau, K. C. Lundberg, K. M. Humphries et al., “Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion,” *The Journal of Biological Chemistry*, vol. 276, no. 32, pp. 30057–30063, 2001.

[52] S. R. Powell, K. J. A. Davies, and A. Divald, “Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrations,” *Journal of Molecular and Cellular Cardiology*, vol. 42, no. 1, pp. 265–269, 2007.

[53] X. Wang, J. Li, H. Zheng, H. Su, and S. R. Powell, “Proteasome functional insufficiency in cardiac pathogenesis,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 301, no. 6, pp. 2207–2219, 2011.

[54] J. Li, K. M. Horak, H. Su, A. Sanbe, J. Robbins, and X. Wang, “Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice,” *The Journal of Clinical Investigation*, vol. 121, no. 9, pp. 3689–3700, 2011.

[55] B. Campbell, J. Adams, Y. K. Shin, and A. M. Lefer, “Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart,” *Journal of Molecular and Cellular Cardiology*, vol. 31, no. 2, pp. 467–476, 1999.

[56] J. Pye, F. Ardesthipour, A. McCain et al., “Proteasome inhibition ablates activation of NF-κB in myocardial reperfusion and reduces reperfusion injury,” *The American Journal of Physiology—Heart and Circulatory Physiology*, vol. 284, no. 3, pp. H1919–H1926, 2003.

[57] W. E. Stansfield, N. C. Moss, M. S. Willis, R. Tang, and C. H. Selzman, “Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury,” *The Annals of Thoracic Surgery*, vol. 84, no. 1, pp. 120–125, 2007.